Drugs / recombinant-human FSH
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT03767218 | Nov 2018 → May 2022 | female infertility | University Hospital Brussels | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT01389713 Comparator | Sep 2008 → Dec 2010 | infertility disorder | Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | recombinant human FSH | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01389713 ↗ |
| Known as | Bemfola | “Start of ovarian stimulation with recombinant-human FSH (Bemfola 225 IU daily) from day 2 of follicular phase onwards.” NCT03767218 ↗ |
| Modality | Protein / enzyme biologic | “recombinant FSH 450 IU daily” PMID 23249758 ↗ Dec 2012 |